Europe Biotechnology Market Thrives with Gene Editing and Biopharma

Europe Biotechnology Market Size, Key Players with Dynamics and Growth

The Europe biotechnology market size is calculated at US$ 418.76 billion in 2024, grew to US$ 465.87 billion in 2025, and is projected to reach around US$ 1208.75 billion by 2034. The market is expanding at a CAGR of 11.30% between 2025 and 2034.

Day by day, Europe is expanding its biotech and pharma facilities across different countries, with the greater adoption of advanced technologies, like AI, gene editing technologies. Moreover, the rising diversity of chronic illnesses is supporting the continuous investment in R&D, along with a phenomenal EU support. The emergence of leading companies, like Roche, Novartis, and Bayer AG, is leveraging sophisticated bio-services and innovation in targeted therapies. Whereas, Nordics are bolstering the cluster of biotech & research academic institutions for novel solutions in genomics, & DNA sequencing.

Key Takeaways

• Europe biotechnology sector pushed the market to USD 418.76 billion by 2024.
• Long-term projections show USD 1208.75 billion valuation by 2034.
• Growth is expected at a steady CAGR of 11.30% in between 2025 to 2034.
• The biotechnology market is set to reach USD 5,036.46 billion by 2034, growing at a 12.5% CAGR on innovation and technology.
• By country, Germany held a major revenue share of 22% of the market in 2024.
• By country, the Nordics are expected to be the fastest-growing during the forecast period.
• By product/service, the biopharmaceuticals segment led with 43% revenue share of the market in 2024.
• By product/service, the bioservices segment is expected to grow at a rapid CAGR in the Europe biotechnology market in the studied years.
• By technology, the DNA sequencing & genomics segment registered dominance with 27% revenue share of the market in 2024.
• By technology, the CRISPR & gene editing segment is expected to witness rapid expansion during 2025-2034.
• By application, the healthcare/medical biotechnology segment accounted for a 47% share of the Europe biotechnology market in 2024.
• By application, the industrial biotechnology segment is expected to grow rapidly in the predicted timeframe.
• By end user, the pharma & biotech companies segment dominated with 45% revenue share of the market in 2024. 
• By end user, the CROs & CDMOs segment is expected to be the fastest-growing during the forecast period.

Key Indicators and Highlights

What is Europe Biotechnology?

The Europe biotechnology market covers biopharmaceuticals, agricultural biotech, industrial biotech, and bio-services across the region. Outsourcing, biotech hubs (Germany, Switzerland, UK, France, Netherlands, Scandinavia), and collaboration between academia and industry are major market drivers. Europe is a global leader in biopharma R&D, cell & gene therapy innovation, and biosimilars adoption, supported by strong regulatory oversight from the European Medicines Agency (EMA) and robust research funding under programs like Horizon Europe. The region’s strengths lie in advanced biologics manufacturing, stem cell research, and synthetic biology, while growing demand for sustainable biofuels, bioplastics, and agri-biotech is diversifying the sector.

What are the Major Trends in the Europe Biotechnology Market?

• Diverse & major leaders of the biotechnology sector are increasingly contributing to the development of advanced therapeutics, platforms, as well as the expansion of their position in the various European countries.
• In July 2025, Oncomatryx Biopharma, a Spanish biotechnology company selected for funding under the European Innovation Council (EIC) Accelerator, with a €2.5 million grant and a €10 million equity investment, to expand the proprietary ADC platform.
• In July 2025, French biotech Ciloa SAS received a €6.5m grant to advance its adiponectin-loaded exosome candidate, APN-sEV, into Phase I safety trials, with enhanced efficacy in type 2 diabetes, obesity, and liver fibrosis.
• In March 2025, Sofinnova Partners, a leading European life sciences venture capital firm, exceeded its target, successfully raising €165M, for a crucial growth of Sofinnova’s biotech acceleration strategy, & with ambitions to further reach additional European countries in the prospective period.

Europe Biotechnology Market: Recent Initiatives

What are the AI Factors Impacting the Europe Biotechnology Market?

The respective market is widely utilizing AI algorithms in various areas of biotechnology, particularly in drug discovery, diagnosis, and personalized treatment. Recently, various companies have presented their approaches, including Cytocast's digital twin patient platform for drug development, Exscientia's AI-assisted drug discovery for Sanofi, and Elixir Health's utilization of AI in fertility treatment by analyzing patient data.

For instance,

• In September 2025, Eli Lilly and Company launched Lilly TuneLab, an artificial intelligence and machine learning (AI/ML) platform that offers biotech companies access to drug discovery models trained on years of Lilly's research data.

Segmental Insights

Which Product/Service Led the Europe Biotechnology Market in 2024?

The biopharmaceuticals segment held 43% revenue share of the market in 2024. The segment is mainly driven by a rise in instances of chronic disease, with a preference for targeted biologics and advancements in gene therapies. In the last few days, a proposed new European biotech act has focused on a holistic approach to regulation and funding, with major investments in R&D by companies, including Sanofi and BioNTech's acceleration into tailored cancer vaccines, and innovative solutions, especially Bayer's cell and gene therapy for Parkinson's research.

Whereas the bioservices segment is anticipated to expand rapidly in the coming era. The presence of a robust research ecosystem, outsourcing R&D, manufacturing, and support functions, is impacting the comprehensive bioservices in Europe. Current milestone steps in bioservices, such as a crucial M&A activity with companies like Genmab acquiring Merus, breakthroughs in gene therapy with UniQure's trial success, and continuous emphasis on soil biodiversity projects like the EU-funded BIOservicES initiative to boost land management and sustainability. 

How did the DNA Sequencing & Genomics Segment Dominate the Market in 2024?

In 2024, the DNA sequencing & genomics segment captured 27% revenue share of the Europe biotechnology market. The segment covers the increasing demand for personalized medicine, technological advances, and escalated government funding for genomic research. Nowadays, Europe is focusing on large-scale, collaborative initiatives like the Genome of Europe (GoE) project, comprising the 1+Million Genomes initiative, over 30 countries are contributing to whole-genome sequencing and data sharing via the secure Genomic Data Infrastructure (GDI) project.

However, the CRISPR & gene editing segment is predicted to expand at a rapid CAGR. Involvement of a strong biotech & pharmaceutical hub, and programs like Horizon Europe with significant funding for genome editing research, supporting both public and private sectors to adopt CRISPR technology. Ongoing research activities, such as a huge contribution of the European Research Council (ERC) in the exploration of CRISPR for applications in cancer gene regulation, neurodegenerative diseases, and other areas, are also propelling the overall market growth.

Which Application Dominated the Europe Biotechnology Market in 2024?

In 2024, the healthcare/medical biotechnology segment held the biggest revenue share of 47% of the market. The segment is eventually fueled by the growing demand for customized treatments based on individual genetic profiles by European consumers and healthcare systems. Alongside, Europe is fostering the transformation of new solutions, such as cardio-immunology and microbiome therapies, and the expansion of antibody-based treatments for autoimmune diseases. The medical sector is imposing advances in gene therapies (like for Huntington's disease) and mRNA vaccines.

Moreover, the industrial biotechnology segment will register the fastest growth during 2025-2034. The arising demand for sustainability approaches, innovation, and supportive government policies is encouraging industrial biotechnology progress. Furthermore, Europe is putting efforts into developments in molecular and computational tools that allow the design of specific traits in microorganisms and plants, resulting in robust and targeted applications. Ongoing manipulation of materials at the nanoscale is bolstering the revolution of drug delivery systems and sophisticated biosensors.

What Made the Pharma & Biotech Companies Dominant in the Market in 2024?

In the Europe biotechnology market, the pharma & biotech companies segment registered dominance with 45% revenue share in 2024. Consistent healthcare expenses are assisting innovative technological advancements in areas like AI and CRISPR, and progress in research areas is fostering the various pharma & biotech companies in Europe. The latest step, like the French startup Bioptimus, is seeking the use of generative AI for drug discovery.  Novo Nordisk is involved in new diabetes and obesity treatments, while companies like Polygon Therapeutics are pursuing new immunotherapies for cardiovascular conditions.

Whereas the CROs & CDMOs segment is predicted to expand fastest in the coming era. The widespread adoption of advanced technologies, like AI & big data, ongoing strategic trend of outsourcing to enhance accessibility of expertise, expenditure, and effectiveness. These facilities are experiencing regulatory and societal pressures, with a raised focus on green chemistry, energy-efficient equipment, and zero-waste manufacturing to optimize sustainability.

Country Analysis

Why did Germany Dominate the Market in 2024?

By capturing 22% revenue share of the Europe biotechnology market, Germany registered dominance in 2024. A prominent catalyst is the prioritizing of biotechnology by both the German government and the EU, with heavy investment in infrastructure, funding innovation, and encouraging biotechnology research and development.

For instance,

• In April 2025, 1Q Health Group, a European CDMO, acquired VivaCell Biotechnology, a contract research organisation based in Germany, to raise itself as a leading provider of premium pharmaceuticals and food supplements across Europe.

Global Biotechnology Market Growth

The biotechnology market is projected to grow from USD 1,744.83 billion in 2025 to USD 5,036.46 billion by 2034, reflecting a CAGR of 12.5% over the period, driven by innovation and technological advancements in the industry.

Thriving Cluster of Biotechnology & Academic Institutions is Driving Nordics

In the future, the Nordics will grow at a rapid CAGR in the Europe biotechnology market. This expansion will be fueled by the rigorous biotech clusters, such as Medicon Valley, spanning Copenhagen (Denmark) and southern Sweden, which act as magnets for R&D. Additionally, the Nordics possess world-class universities and research institutions, especially the Karolinska Institute in Sweden and the Technical University of Denmark. These institutions are promoting alliance among academia and industry, leading to a robust pipeline of talent and spin-off companies.

For this market,

• In July 2025, Danish quantum investment was supported to accelerate EU biotech and medical research.

Key Companies and Their contributions and offerings

• Roche (Switzerland)- A major player facilitating a diverse portfolio of biotechnology products and services.
• Novartis (Switzerland)- A key company offering a focus on advanced technology platforms to evolve transformative medicines.
• Lonza Group (Switzerland)- It is providing coverage of the comprehensive product lifecycle, from early-phase development to commercial manufacturing.
• Bayer AG (Germany)- A leading player facilitating biotechnology-driven products and research across its Pharmaceuticals and Crop Science divisions. 
• Boehringer Ingelheim (Germany)- It offers extensive biotechnology capabilities, mainly through its BioXcellence contract development and manufacturing (CDMO) service.

Top Companies in the Market

• Merck KGaA (Germany)
• Qiagen (Germany/Netherlands)
• Evotec SE (Germany) 
• Sanofi (France)
• Ipsen (France)
• Servier (France)
• AstraZeneca (UK)
• GSK (UK)
• Oxford Biomedica (UK)
• Genmab (Denmark)
• Bavarian Nordic (Denmark)
• Novo Nordisk (Denmark)
• Actelion (Switzerland, J&J subsidiary)
• BioNTech (Germany)
• CureVac (Germany)

What are the Recent Developments in the Europe Biotechnology Market?

• In September 2025, Rezon Bio today unveiled its European contract development and manufacturing organization (CDMO) for biologics.
• In September 2025, Takara Bio Europe launched Cellartis MSC EV Wonder, a defined, xeno-free medium created for the scalable production of extracellular vesicles (EVs) from human mesenchymal stem cells (MSCs).
• In June 2025, Outlook Therapeutics, Inc., a biopharmaceutical company, announced that LYTENAVA (bevacizumab gamma) is commercially available in Germany and the UK for the treatment of wet age-related macular degeneration (wet AMD). 
• In January 2025, Enhanc3D Genomics, an innovator in 3D genomics technology, launched a suite of integrated multi-omics solutions to boost and improve the precision of drug discovery.

Segments Covered in the Report

By Product/Service

• Biopharmaceuticals
• Bioinformatics
• Bioagriculture
• Bioindustrial
• Bioservices

By Technology

• DNA Sequencing & Genomics
• Fermentation & Cell Culture
• Tissue Engineering & Regenerative Medicine
• CRISPR & Gene Editing
• Nanobiotechnology
• Others (proteomics, metabolomics, synthetic biology)

By Application

• Healthcare/Medical Biotechnology
• Agricultural Biotechnology
• Industrial Biotechnology
• Environmental Biotechnology
• Marine & Other Applications

By End User 

• Pharma & Biotech Companies
• Academic & Research Institutions
• CROs & CDMOs
• Hospitals & Clinics

By Country

• Germany
• UK
• Switzerland
• France
• Nordics
• Italy
• Spain
• Others (Netherlands, Belgium, Austria, Eastern Europe)